Unclear

DIREKHT

ForPost-operative HNSCC, low contralateral nodal risk subgroup

TL;DRPost-op RT de-intensification in HNSCC: contralateral neck sparing and/or primary CTV dose reduction to 56 Gy; no effect size reported in source tweet.

vs leading data

De-escalation context: ECOG-ACRIN 3311 (HPV+ oropharynx) and NRG HN002 established dose/volume reduction as feasible; DIREKHT extends this logic to post-op setting with anatomic field reduction

Radiation Curative Unclear

5 details

Methods

🔍 Post-operative RT de-intensification trial in HNSCC
🔍 Two strategies evaluated: contralateral neck sparing in selected pts and/or primary CTV dose reduction to 56 Gy (vs standard 60-66 Gy)

Results

📊 No effect size, HR, or primary endpoint result reported in source tweet (content truncated)

Critique

⚠️ De-intensification trials in post-op HNSCC carry risk of local-regional relapse if patient selection criteria are not tightly specified; contralateral neck failure rates in similar series run 3-8%

Notes

❓ Whether contralateral neck sparing and dose reduction are evaluated as independent arms or a composite de-intensification strategy is unclear from source

Open questions

Local-regional control rates with contralateral neck sparing vs elective nodal irradiation
Which patient subgroup (HPV+, N stage, margin status) benefits from 56 Gy de-escalation
Whether both de-intensification strategies are independently randomized or combined

📚 Sources · 🐦 1 tweet

There are tremendous opportunities to improve post-operative radiotherapy in HNSCC. The DIREKHT trial is an excellent example of such work, in which they spared the contralateral neck in a specified group of patients and/or reduced the primary CTV dose to 56 Gy.

The details… https://t.co/7W84LYIofR
— David Sher (@DavidSherMD) May 16, 2026